Table 1 Baseline characteristics of patients initiating antihypertensive treatment in 2014–2016 in the JMDC database
From: Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan
Characteristics | All, N (%) | 31,592 | (100.0) |
|---|---|---|---|
Sex, N (%) | |||
Female | 13,003 | (41.2) | |
Male | 18,589 | (58.8) | |
Age years, mean (SD) | 51.7 | (8.6) | |
Age group, N (%) | |||
30–49 | 12,677 | (40.1) | |
50–59 | 12,943 | (41.0) | |
60–74 | 5972 | (18.9) | |
First prescription, N (%) | |||
Monotherapy | |||
ACEI | 661 | (2.1) | |
ARB | 13,289 | (42.1) | |
BB | 2211 | (7.0) | |
CCB | 13,808 | (43.7) | |
Thiazides | 169 | (0.5) | |
Combination therapy | 1454 | (4.6) | |
Comorbid condition absence, N (%) | 17,446 | (55.2) | |
Baseline comorbidities, N (%) | |||
Cancer | 508 | (1.6) | |
Cerebrovascular disease | 173 | (0.5) | |
Chronic renal failure | 231 | (0.7) | |
Chronic respiratory disease | 3452 | (10.9) | |
Hyperuricemia/gout | 4250 | (13.5) | |
Liver disease | 1494 | (4.7) | |
Obesity | 324 | (1.0) | |
Peripheral vascular disease | 245 | (0.8) | |
Baseline medications, N (%) | |||
Antidiabetics | 2571 | (8.1) | |
Anxiolytics/hypnotic sedatives | 4532 | (14.3) | |
H2 blockers | 2597 | (8.2) | |
Lipid-modifying agents | 5687 | (18.0) | |
NSAID | 11,949 | (37.8) | |
SSRI/SNRI | 1028 | (3.3) | |
Hospitalization (baseline period), N (%) | 1717 | (5.4) | |
Number of times drugs were dispensed, N (%) | |||
0 | 7610 | (24.1) | |
1–6 | 14,856 | (47.0) | |
≥7 | 9126 | (28.9) | |
Number of concurrently prescribed drugs on the index date, N (%) | |||
0 | 16,798 | (53.2) | |
1–2 | 10,044 | (31.8) | |
≥3 | 4750 | (15.0) | |
Types of medical institutions/number of beds, N (%) | |||
Clinic | |||
0–19 | 25,171 | (79.7) | |
Hospital | |||
20–199 | 2885 | (9.1) | |
≥200 | 3536 | (11.2) | |
